The understanding of multiple sclerosis has come a long way since the first treatments for the disease were developed and made available in the early 1990’s. Not only do we have increased knowledge of the immune system and the pathophysiology of MS, but we also have long-term data showing the effect of disease-modifying therapy. In this year’s program, divided into 2 parts for easier viewing, Dr. Omar Khan and his panel of MS specialists will discuss emerging themes of clinical interest, including practice issues, imaging data and the next generation of MS therapeutics.
Part 1 of this lively discussion will include information on some of the latest findings about the immunopathology of MS, and updated information about the clinical effects of disease-modifying therapy. In Part 2, new data from imaging studies and consideration of the next generation of MS Therapeutics in light of current information will be the topics for discussion.
Recorded live on October 28, 2008, Detroit, MI
Parts 1 and 2 combined are designated for a maximum of 2.75 AMA PRA Category 1 Credits(s)™
This continuing medical education activity is jointly sponsored by Ciné-Med Inc. and Astute Technology.


This activity is supported by an educational grant from Teva Neuroscience.
Moderator
Panelist
Panelist
Panelist
In 2 hours of lively discussion, four expert neurologists—3 neuroimaging specialists and a leading clinical investigator—discuss the evolution and clinical potential of magnetic resonance imaging techniques, in light of the new research gains in Multiple Sclerosis.